Incidence of adverse oesophageal and gastric events in alendronate users

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 5, 2000, Pages 371-376

  Park, Byung Joo ^a,c   Clouse, Jon ^b   Shatin, Deborah ^b,e   Stergachis, Andy ^c,d  

^a Seoul National University   (South Korea)

^b UNITEDHEALTH GROUP   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UnitedHealth Group ^*

^e United Behavioral Health   (United States)

Author keywords

Adverse oesophageal or gastric effects; Alendronate; Epidemiology; Incidence

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; DUODENITIS; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS PERFORATION; ESOPHAGUS ULCER; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GENDER; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH DISEASE; STOMACH ULCER;

EID: 0033764072     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1557(200009/10)9:5<371::AID-PDS514>3.0.CO;2-7     Document Type: Article

References (22)

1. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women
2. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal Salmon calcitonin
3. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
4. Efficacy and safety of drugs for Paget's disease of bone
5. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
6. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
7. Esophagitis and alendronate
8. Multiple ulcerative esophagitis caused by alendronate
9. Esophageal ulceration due to alendronate
10. Alendronate-induced ulcerative esophagitis
11. Improper alendronate administration and a case of pill esophagitis
12. Esophagitisi associated with the use of alendronate
13. A new probable increasing cause of esophageal ulceration: Alendronate
14. Oesophageal stricture associated with alendronic acid
15. Alendronate causes gastric mucosal damage similar to NSAIDs
16. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation
17. Record linkage studies for post-marketing drug surveillance: Data quality and considerations
18. Using claims data for epidemiologic research: The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population
19. The risks and costs of upper gastrointestinal disease attributable to NSAIDs
20. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury